Senior/Principal Scientist, In Vitro Biology Team Lead

Senior/Principal Scientist, In Vitro Biology Team Lead

Location: New York, New York / Onsite

Reporting to: Senior Director, Head of Radiopharmacology

Why This Role. Why Now.

Radiopharmaceuticals are one of the fastest growing and most strategically active segments in biotech and Actinium Pharmaceuticals (NYSE: ATNM) is at the forefront.

Actinium is building first-in-class targeted radiotherapies by uniquely integrating deep radiochemistry expertise with cancer biology insight. Our pipeline spans solid tumors and hematologic malignancies and includes multiple platform-level partnering opportunities across alpha-emitter therapeutics, combinations, conditioning agents, and manufacturing IP.

We are seeking a highly motivated individual to join Actinium Pharmaceuticals and help lead the next wave of innovation in targeted radiotherapies.

The Opportunity

Actinium is seeking a highly motivated and accomplished scientist to lead the next wave of breakthroughs in targeted radiotherapies as our Senior/Principal Scientist, In Vitro Biology Team Lead . In this hands-on, high-impact role, you will serve as the scientific leader for all in vitro assay activities across our Oncology pipeline, helping to advance novel targeted radiotherapies from discovery through IND-enabling studies and supporting translational studies for clinical development.

You will join a fast-paced, science-driven biotechnology company developing first-in-class targeted radiotherapies with the potential to transform outcomes for patients with solid tumors and hematologic malignancies. The ideal candidate will possess deep expertise in in vitro pharmacology, ex vivo studies, and the development, validation, and execution of immunological and bioanalytical assays. A proven track record of hands-on experience performing, optimizing, and troubleshooting complex in vitro and ex vivo assays is required. Experience in immunology, including flow cytometry and immunoassay development, is highly desirable.

This unique opportunity will allow you to drive innovation across multiple areas, including tumor biology, cell signaling, antibody binding and internalization, cytotoxicity assays, and in vitro pharmacology studies evaluating both monotherapies and combination therapies. You will also contribute to the translational development of targeted radiotherapies through quantitative data analysis, including IC₅₀, Kd, and Bmax determination and other pharmacological parameters, while helping to build and expand analytical assay capabilities within a rapidly growing organization.

Key Responsibilities

• Lead the development, validation, and execution of in vitro pharmacology assays to evaluate target biology, tumor cell signaling, antibody binding and internalization, cytotoxicity, biomarker development, cytokine release, and other cellular responses to support drug screening
• Lead the development, qualification, and execution of in vitro assays, and oversee the maintenance, culture, passaging, and banking of multiple cell lines to support research and development objectives
• Design, perform, and interpret multiparameter flow cytometry and other in vitro and ex vivo assays (e.G., receptor occupancy, receptor density, PK/PD biomarker analyses, tumor cell isolation, and blood cell characterization) to assess target engagement and cellular responses
• Design and execute experiments supporting candidate selection, lead optimization, target validation, and translational biomarker development for targeted radiotherapies and related biologic modalities.
• Develop and qualify assays to support IND-enabling studies, regulatory submissions, and clinical translational research.
• Serve as the scientific subject matter expert for In vitro Biology and bioanalytical assays across Discovery, Translational, and Development-stage programs
• Provide scientific leadership, mentorship, performance management, and career development for Research Associates and junior scientists
• Manage and oversee experimental activities conducted by external collaborators and contract research organizations (CROs), while partnering closely with other functional teams and senior leadership to advance programs through preclinical development
• Analyze, interpret, and communicate scientific findings through study reports, technical presentations, internal cross-functional team meetings, and presentations at external scientific conferences

What You Bring

• 5-7 years of research experience for in vitro pharmacology and assay development in an industry setting
• Demonstrated success in designing and executing comprehensive experimental plans on schedule to support IND packages.
• Prior experience with biologic modalities, such as radiopharmaceuticals or antibody-drug conjugates (ADCs).
• Demonstrated experience leading Research Associates for in vitro pharmacology studies.
• Proficiency in multiparameter flow cytometry, including panel design and data analysis.
• Experience developing and validating bioanalytical assays.
• Proven ability to independently lead and advance multiple research programs with minimal supervision.
• Track record of managing external collaborations, including CROs and vendor relationships.
• Ability to collaborate effectively across scientific disciplines to achieve business objectives.
• Strong record of communicating scientific findings to both internal and external audiences.
• Strong knowledge of, and interest in, cancer biology, including disease states, mutational profiles, and tumor cell drivers.
• Ability to lead a team of junior scientists is a plus.

Education

• PhD in Biology, Immunology, Pharmacology or a related field. Postdoctoral training in oncology, immunology, translational biology, or related areas is preferred.

Actinium Pharmaceuticals develops targeted radiotherapies to improve patient outcomes. Our lead candidate, ATNM-400, is a first-in-class Actinium-225 (Ac-225) therapy for prostate cancer, lung cancer, and breast cancer, showing superior preclinical efficacy and synergy with existing treatments. Actimab-A, targeting CD33 for AML and other myeloid malignancies, has demonstrated high remission rates in patients and is advancing to pivotal clinical trials, including combination studies with Venetoclax, ASTX-727, and now PD-1 inhibitors (KEYTRUDA, OPDIVO) for solid tumors. Additional clinical programs include Iomab-ACT and Iomab-B for transplant conditioning. Actinium also pursues preclinical solid tumor programs and holds ~240 patents, including for Ac-225 production. Building on our expertise and leadership in targeted radiotherapies, Actinium is rapidly accelerating our investigational research efforts and is looking for talented individuals to join the team

EEO & Compliance

Actinium is an equal opportunity employer. It is our policy and practice to employ, promote, and otherwise treat all employees and applicants on the basis of merit, qualifications, and competence. The company’s policy prohibits unlawful discrimination, including but not limited to, discrimination on the basis of protected Veterans status, individuals with disabilities status, and consistent with all federal, state or local laws.

Featured benefits

Medical insurance, Vision insurance, Dental insurance, 401(k)